Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa
Rebecca Jepsen, C M Edwards, Akshay Flora, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 4, pp. 694-702
Closed Access | Times Cited: 19

Showing 19 citing articles:

Hidradenitis Suppurativa
James P. Pham, John W. Frew
Dermatologic Clinics (2025) Vol. 43, Iss. 2, pp. 179-191
Closed Access | Times Cited: 3
Unravelling the complex pathogenesis of hidradenitis suppurativa
John W. Frew
British Journal of Dermatology (2025) Vol. 192, Iss. Supplement_1, pp. i3-i14
Open Access | Times Cited: 2
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
James G. Krueger, John W. Frew, Gregor B. E. Jemec, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 2, pp. 149-162
Open Access | Times Cited: 29
Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm
Carlo Alberto Maronese, Chiara Moltrasio, Giovanni Genovese, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 5, pp. 525-545
Closed Access | Times Cited: 27
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa
Margaret M. Lowe, Jarish N. Cohen, Madison I. Moss, et al.
JCI Insight (2023)
Open Access | Times Cited: 13
Serum Immunoglobulin G Levels and Nicastrin Variation in Hidradenitis Suppurativa
Dillon Mintoff, Nikolai Paul Pace
JAMA Dermatology (2025)
Closed Access
Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo
Akshay Flora, Rebecca Jepsen, Emily Kozera, et al.
PLoS ONE (2023) Vol. 18, Iss. 11, pp. e0282763-e0282763
Open Access | Times Cited: 8
A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment
Amirhossein Heidari, Yekta Ghane, Nazila Heidari, et al.
International Immunopharmacology (2023) Vol. 127, pp. 111435-111435
Closed Access | Times Cited: 7
Advances in Hidradenitis Suppurativa Pathogenesis and Therapies from the Symposium on HS Advances 2023
Sarah Park, Alexis Bell, Ruby Gibson, et al.
Journal of Investigative Dermatology (2024) Vol. 144, Iss. 8, pp. 1681-1684
Closed Access | Times Cited: 2
Hidradenitis suppurativa: key insights into treatment success and failure
Kelsey R. van Straalen, Vincent Piguet, Jóhann E. Guðjónsson
Journal of Clinical Investigation (2024) Vol. 134, Iss. 21
Open Access | Times Cited: 2
Australasian hidradenitis suppurativa management guidelines
John W. Frew, Annika Smith, Pablo Fernández‐Peñas, et al.
Australasian Journal of Dermatology (2024)
Open Access | Times Cited: 2
Mast cells are upregulated in hidradenitis suppurativa tissue, associated with epithelialized tunnels and normalized by spleen tyrosine kinase antagonism
Akshay Flora, Rebecca Jepsen, Emily Kozera, et al.
Experimental Dermatology (2023) Vol. 33, Iss. 1
Open Access | Times Cited: 6
Hidradenitis Suppurativa: An Interdisciplinary Problem in Dermatology, Gynecology, and Surgery—Pathogenesis, Comorbidities, and Current Treatments
Agnieszka Nowak-Liduk, Diana Kitala, Gabriela Ochała-Gierek, et al.
Life (2023) Vol. 13, Iss. 9, pp. 1895-1895
Open Access | Times Cited: 6
DNA methylation patterns of circadian and ultradian genes are altered in the peripheral blood of patients with hidradenitis suppurativa
Uppala Radhakrishna, Uppala Ratnamala, Devendrasinh Jhala, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial
Akshay Flora, Rebecca Jepsen, James P. Pham, et al.
Journal of Investigative Dermatology (2023) Vol. 144, Iss. 4, pp. 786-793.e1
Open Access | Times Cited: 3
The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa
Akshay Flora, James P. Pham, Rebecca Jepsen, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 4
Closed Access | Times Cited: 2
Innovations in Hidradenitis Suppurativa
Sarah Park, Jennifer L. Hsiao, Maria Aleshin
Dermatologic Clinics (2024) Vol. 43, Iss. 1, pp. 35-53
Closed Access
Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow
Daniella Jaguan, Kim Thuy Nguyen, Noah Goldfarb
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. S31-S36
Closed Access
Quoi de neuf en thérapeutique dermatologique ?
M. Samimi
Annales de Dermatologie et de Vénéréologie - FMC (2023) Vol. 3, Iss. 8, pp. 8S50-8S65
Closed Access
Page 1

Scroll to top